Moving Toward Precision Medicine in Treating Newly Diagnosed Acute Myeloid Leukemia


Presented by the Johns Hopkins School of Medicine and

the Institute for Johns Hopkins Nursing.

Supported by educational grants from Agios, Inc., and Jazz Pharmaceuticals, Inc.

OVERVIEW
AML is the most common acute leukemia in adults and is characterized by the clonal expansion of myeloblasts in the peripheral blood and bone marrow, resulting in ineffective hemtopoiesis and bone marrow failure. AML is a heterogeneous disease, with a plethora of genetic mutations and translocations that contribute to disease initiation and progression. The standard approach to therapy has been induction with cytarabine + anthracycline, followed by consolidation therapy. Recent advances have led to the development of novel, targeted agents and improved chemotherapy options, that have increased PFS and OS in patients with AML. These agents represent the first steps to individualizing patient care. Using patient cases, this activity reviews the pathophysiology and current state of management of AML, highlighting the optimal incorporation of targeted agents for newly-diagnosed, de novo AML and improved chemotherapeutic options for treatment-related AML.

GOAL
This activity will educate oncology/hematology health care providers on recent advances in the management of newly diagnosed AML, based on the identification of key molecular targets. The efficacy and safety data for the most recently FDA approved and emerging agents for newly diagnosed AML will be reviewed. Participants will gain an understanding of the rationale and approach to optimizing patient care based on the patient's characteristics and a molecular analysis of the disease.

TARGET AUDIENCE
This activity is intended for healthcare providers who manage patients with acute myeloid leukemia, including hematologists, medical oncologists, oncology nurses, nurse practitioners, and physicians’ assistants. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  •   • IDENTIFY the challenges and unmet clinical needs in the treatment of newly diagnosed AML and the importance of key molecular targets and precision medicine.
  •   • REVIEW the efficacy and safety data for the most recently FDA approved and emerging agents for newly diagnosed AML.
  •   • IMPLEMENT the use of novel agents into individualized treatment plans for patients with newly diagnosed AML.

The Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

CE INFORMATION
Accreditation Statements – This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint accme_logo providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statements – The Johns Hopkins University School of Medicine designates this enduring material internet activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This .5 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until December 18, 2020.

The estimated time to complete this activity: 30 minutes.

Release date: December 19, 2019     Expiration date: December 19, 2020

Policy on Presenter and Provider Disclosure
It is the policy of the Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing that the presenter and provider globally disclose conflicts of interest. The Johns Hopkins School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:

Planner Disclosures
Dr Ettinger reports receiving a consulting fee from BeyondSpring Inc., Boehringer Ingelheim Vetmedica GmbH, Bristol-Myers Squib Company, Eli Lilly and Company, Guardant Health, Inc., Genentech, Inc., and sanofi-aventis.

Participating Faculty Disclosures
Dr Gojo reports serving as a principal investigator for Amgen, Inc, Amphivena Therapeutics, Inc., and Merck & Co, Inc; and reports that her spouse serves as a principal investigator for Genentech, Inc.

No other individual with the opportunity to affect this educational content has indicated any financial interests or relationships with a commercial entity.

Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

FACULTY
Johns Hopkins School of Medicine Chair and Planner
David S. Ettinger, MD

Alex Grass Professor of Oncology
Sidney Kimmel Comprehensive Cancer
Baltimore, Maryland

Faculty Author
Ivana Gojo, MD
Associate Professor of Oncology
DJohns Hopkins School of Medicine
Co-Director, Leukemia Drug Development Program
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Peer Reviewer
Daniel Suzman, MD

Department of Oncology
Sibley Memorial Hospital
Baltimore, Maryland

Nurse Planner
Rebecca Barshick, RN, MSN
Nurse Educator
The Institute for Johns Hopkins Nursing
Baltimore, Maryland

Nurse Reviewer
MiKaela Olsen, APRN-CNS, MS, AOCNS, FAAN
Oncology and Hematology Clinical Nurse Specialist
Ambulatory Oncology
Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins Hospital and Greenspring Oncology
Baltimore, Maryland

Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

OFF-LABEL PRODUCT DISCUSSION – No faculty member has indicated that their presentation will include information on off-label products.

DISCLAIMER – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

"The Office of Continuing Medical Education at the Johns Hopkins School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only."

For CME questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu.
Johns Hopkins School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY INSTRUCTIONS
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, an interactive case study, and a CE postassessment and evaluation. All 3 sections must be completed to receive CE credit. A certificate of participation will be available online immediately following successful completion of the activity.

Preassessment

Moving Toward Precision Medicine in Treating Newly Diagnosed Acute Myeloid Leukemia
Ivana Gojo, MD

Postassessment and Evaluation

This activity was developed in collaboration with ASiM.


© 2019 - Hematology Consults